WZ811

CAS No. 55778-02-4

WZ811( WZ811 | WZ-811 | WZ 811 )

Catalog No. M15027 CAS No. 55778-02-4

WZ811 is a novel small molecular and potency CXCR4 antagonist with EC50 of 0.3 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 43 In Stock
10MG 55 In Stock
25MG 104 In Stock
50MG 167 In Stock
100MG 233 In Stock
200MG 302 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    WZ811
  • Note
    Research use only, not for human use.
  • Brief Description
    WZ811 is a novel small molecular and potency CXCR4 antagonist with EC50 of 0.3 nM.
  • Description
    WZ811 is a novel small molecular and potency CXCR4 antagonist with EC50 of 0.3 nM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    WZ811 | WZ-811 | WZ 811
  • Pathway
    Autophagy
  • Target
    CXCR
  • Recptor
    CXCR4
  • Research Area
    Inflammation/Immunology
  • Indication
    ——

Chemical Information

  • CAS Number
    55778-02-4
  • Formula Weight
    290.36
  • Molecular Formula
    C18H18N4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 30 mg/mL (103.32 mM)
  • SMILES
    C1(CNC2=NC=CC=C2)=CC=C(CNC3=NC=CC=C3)C=C1
  • Chemical Name
    N,N'-(1,4-phenylenebis(methylene))bis(pyridin-2-amine)

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zhan W, et al. J Med Chem, 2007, 50(23), 5655-5664.
molnova catalog
related products
  • Mogamulizumab

    Mogamulizumab (KW-0761) is a monoclonal antibody targeting T cell CC chemokine receptor 4.

  • TC14012

    TC14012, a serum-stable derivative of T140, is a selective and peptidomimetic CXCR4 antagonist with an IC50 of 19.3 nM. TC14012 is a potent CXCR7 agonist with an EC50 of 350 nM for recruiting β-arrestin 2 to CXCR7. TC14012 has anti-HIV activity and anti-cancer activity.

  • AZD8797

    AZD8797 (KAND567) is an orally available, selective and potent human CX3CR1-converting antagonist with inhibitory effects on CX3CR1 and CXCR2.